- Trials with a EudraCT protocol (757)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
757 result(s) found for: Chronic Hepatitis C AND Hepatitis C.
Displaying page 6 of 38.
| EudraCT Number: 2014-001496-31 | Sponsor Protocol Number: M11-665 | Start Date*: 2014-12-18 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and C... | |||||||||||||
| Medical condition: Hepatitis C Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) AT (Completed) ES (Completed) IT (Completed) GR (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004200-38 | Sponsor Protocol Number: 64294178HPC2001 | Start Date*: 2016-09-12 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Phase 2b, Multicenter, Randomized, Open-label Study to investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naïv... | |||||||||||||
| Medical condition: Chronic Hepatitis C virus infection. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-003593-85 | Sponsor Protocol Number: VX-950HPC3005 | Start Date*: 2012-04-26 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibro... | |||||||||||||
| Medical condition: Chronic hepatitis C infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) IT (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) HU (Completed) IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020444-36 | Sponsor Protocol Number: TMC435-TiDP16-C208 | Start Date*: 2011-02-14 | |||||||||||
| Sponsor Name:Janssen R&D Ireland | |||||||||||||
| Full Title: A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alf... | |||||||||||||
| Medical condition: Hepatitis C Virus (HCV) in treatment naïve patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003607-59 | Sponsor Protocol Number: HCV_AMH_16 | Start Date*: 2017-03-07 | |||||||||||
| Sponsor Name:DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE | |||||||||||||
| Full Title: An Open-Label Study to Evaluate Long-Term Results With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) on ovarian function in fertile women With Genotype 1 and 4 Ch... | |||||||||||||
| Medical condition: Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002446-23 | Sponsor Protocol Number: GS-US-342-1143 | Start Date*: 2017-01-19 | ||||||||||||||||
| Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
| Full Title: A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection | ||||||||||||||||||
| Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) BE (Completed) Outside EU/EEA IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-002920-14 | Sponsor Protocol Number: VX-950-TiDP24-C209 | Start Date*: 2007-11-14 | |||||||||||
| Sponsor Name:Tibotec BVBA | |||||||||||||
| Full Title: A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection | |||||||||||||
| Medical condition: Hepatitis C infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) FR (Completed) SE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001682-27 | Sponsor Protocol Number: GS-US-342-1140 | Start Date*: 2014-08-19 | ||||||||||||||||
| Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
| Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subje... | ||||||||||||||||||
| Medical condition: Chronic Hepatitis C Virus Infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) IT (Completed) FR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-005287-21 | Sponsor Protocol Number: AI444-046 | Start Date*: 2012-02-09 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... | |||||||||||||
| Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002748-28 | Sponsor Protocol Number: GS-US-248-0131 | Start Date*: 2011-11-30 | ||||||||||||||||
| Sponsor Name:Gilead Sciences Inc. | ||||||||||||||||||
| Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subject... | ||||||||||||||||||
| Medical condition: Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-000456-42 | Sponsor Protocol Number: GS-US-256-0148 | Start Date*: 2011-10-04 | ||||||||||||||||
| Sponsor Name:Gilead Sciences Inc. | ||||||||||||||||||
| Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treat... | ||||||||||||||||||
| Medical condition: Genotype 1 Hepatitis C Virus Infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) BG (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-004556-71 | Sponsor Protocol Number: P05514 | Start Date*: 2009-05-25 | ||||||||||||||||||||||||||
| Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation | ||||||||||||||||||||||||||||
| Full Title: Estudio de un solo grupo para facilitar tratamiento con boceprevir a sujetos con el genotipo 1 del virus de la hepatitis C crónica que no han respondido a peginterferón/ribavirina en estudios previ... | ||||||||||||||||||||||||||||
| Medical condition: Hepatitis C Crónica | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Completed) FR (Completed) DE (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2015-002401-10 | Sponsor Protocol Number: TAL2015 | Start Date*: 2015-10-12 | |||||||||||
| Sponsor Name:FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA OPERA DI SAN PIO DA PIETRELCINA OSPEDALE IRCCS | |||||||||||||
| Full Title: Pilot multicenter open label study on treatment with Sofosbuvir/Ledipasvir FDC for patients with thalassemia major and HCV infection. | |||||||||||||
| Medical condition: Patients with thalassemia major and HCV infection either naïve or on nucleo(s)tide analogs treatment, data on Sofosbuvir-based treatment are currently lacking, while, due to the long infection dura... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000459-25 | Sponsor Protocol Number: TMC435HPC2017 | Start Date*: 2015-05-12 | |||||||||||
| Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
| Full Title: A Phase 2, 2-panel, Open-label, Randomized Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and L... | |||||||||||||
| Medical condition: Chronic Hepatitus C Virus (HCV) Genotype 1 Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004250-34 | Sponsor Protocol Number: TMC435HPC2018 | Start Date*: 2015-05-11 | |||||||||||
| Sponsor Name:Janssen R&D Ireland | |||||||||||||
| Full Title: A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatit... | |||||||||||||
| Medical condition: Hepatitis C Virus (HCV) genotype-1b and 4 Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000178-36 | Sponsor Protocol Number: VHCRP1309 | Start Date*: 2016-04-28 | |||||||||||
| Sponsor Name:University of New South Wales | |||||||||||||
| Full Title: A phase II, open-label, single arm, multicentre, international trial of sofosbuvir and GS-5816 for people with chronic hepatitis C virus infection and recent injection drug use | |||||||||||||
| Medical condition: Chronic hepatitis C all genotypes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-000480-87 | Sponsor Protocol Number: GS-US-367-1175 | Start Date*: 2019-06-05 | ||||||||||||||||
| Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
| Full Title: A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Chil... | ||||||||||||||||||
| Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) GB (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-012579-90 | Sponsor Protocol Number: 1220.40 | Start Date*: 2009-08-04 | |||||||||||||||||||||
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||||||||||||
| Full Title: Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... | |||||||||||||||||||||||
| Medical condition: chronic hepatitis C | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) FR (Completed) AT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2014-004939-39 | Sponsor Protocol Number: GS-EU-174-1403 | Start Date*: 2015-05-26 | |||||||||||
| Sponsor Name:Gilead Sciences International Ltd. | |||||||||||||
| Full Title: Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... | |||||||||||||
| Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003024-31 | Sponsor Protocol Number: DAA-HCV | Start Date*: 2015-11-06 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA | |||||||||||||
| Full Title: Anti-viral responses in patients with chronic HCV infection treated with DAA alone or with PEG-IFN based regimens | |||||||||||||
| Medical condition: CHRONIC HEPATITIS C | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.